Baird reiterates an 'Outperform' on Pharmasset (VRUS); Another Positive Update on Wholly-Owned Assets '7977 and '938
Tweet Send to a Friend
Baird reiterates an 'Outperform' on Pharmasset (NASDAQ: VRUS), PT $54.
Baird analyst says, "Reiterate rating on another positive update for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "Reiterate rating on another positive update for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
